Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (231) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (26) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (22) Apply Team member filter
- Videos (16) Apply Videos filter
- Financial reports (12) Apply Financial reports filter
- Webcasts and audio (12) Apply Webcasts and audio filter
- Analyst (11) Apply Analyst filter
- Investor contact (6) Apply Investor contact filter
- Event (4) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Corporate governance
The policy of the Board is to manage the affairs of Oxford Biomedica to the highest standards of corporate governance and in acco
Warning to shareholders
Oxford Biomedica is obliged by law to make its share register publicly available and, as a result, some shareholders may receive
Balancing risk to optimise reward
Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation.
Harnessing the CAR-T
Over the past year, Oxford BioMedica’s outlook has been transformed.
New non-dilutive funding to expand production
Oxford BioMedica has secured a $50m loan facility from Oberland Capital.